Bagsværd, Denmark, 8 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Kasim Kutay | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | ADRs | ||||
| Identification code | NVO | |||||
| b) | Nature of the transaction | Purchase of ADRs | ||||
c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 837.52 | 83 ADRs | |||||
| d) | Aggregated information
| 83 ADRs | ||||
| e) | Date of the transaction | 2024-08-07 | ||||
| f) | Place of the transaction | New York Stock Exchange | ||||
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Maha Kutay | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Closely associated person to Kasim Kutay, member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Purchase of shares | ||||
c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 846.80 | 255 shares | |||||
| DKK 848.00 | 1,650 shares | |||||
| DKK 853.70 | 65 shares | |||||
| d) | Aggregated information
| 1,970 shares | ||||
| e) | Date of the transaction | 2024-08-07 | ||||
| f) | Place of the transaction | Nasdaq Copenhagen | ||||
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Choi Lai Christina Law | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | ADRs | ||||
| Identification code | NVO | |||||
| b) | Nature of the transaction | Purchase of ADRs | ||||
c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 850.67 | 2,000 ADRs | |||||
| d) | Aggregated information
| 2,000 ADRs | ||||
| e) | Date of the transaction | 2024-08-07 | ||||
| f) | Place of the transaction | New York Stock Exchange | ||||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
Ambre James-Brown | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
Jacob Martin Wiborg Rode | Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
David Heiberg Landsted | Mark Joseph Root (US) |
Sina Meyer | Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Company announcement No 59 / 2024
Attachment
